奧密克戎變異株導致肺炎或重症比例比流感低
近日，關於奧密克戎變異株致病力減弱的話題受到廣泛關注。國務院聯防聯控機制邀請呼吸危重症專家、北京市呼吸疾病研究所所長童朝暉，針對大家關心的問題予以解答。
童朝暉表示，國際和國內監測數據證實，奧密克戎變異株及其進化分支的致病力和毒力相比原始株和德爾塔等變異株明顯減弱。
首都醫科大學附屬北京朝陽醫院副院長 北京市呼吸疾病研究所所長 童朝暉：其實奧密克戎也已經變了好幾個分支了，我們從臨牀觀察到它這個奧密克戎的特點，傳播性比較強，就是傳得比原來那些原始株要快，但是它主要還是以上呼吸道的症狀爲主，也就是說很多人，甚至都沒有像高熱的那種，就是中低熱，然後嗓子不舒服、咳嗽，主要集中在上呼吸道。從我們國內這段時間來看，各個省市的報道，無症狀加輕型的在90%以上。那麼像普通型，所謂我們說的普通型就是肺裏有影子有肺炎的都不多。那麼重型危重型實際上大家知道，新冠的重型、危重型指的是要吸氧，要給氧療，這個比例就更少，因爲我最近也是在北京的一線，到定點醫院去查房會診，真正的因爲新冠肺炎導致的需要住院、需要插管上呼吸機的也就三四例。
童朝暉表示，奧密克戎變異株引起重症和死亡的比例明顯低於之前原始株和關切變異株，這既是奧密克戎變異株的特點，也與人羣接種疫苗免疫水平提高和國家採取的積極預防策略有關。與2009年全球流感流行時期相比，目前奧密克戎變異株導致肺炎或者重症、危重症的比例相對較低。
首都醫科大學附屬北京朝陽醫院副院長 北京市呼吸疾病研究所所長 童朝暉：2009年全球，包括咱中國流感流行，那個時候出現流感肺炎的比例也是非常高，我記得我那會兒也會診了不少，而且ICU裏住的全是流感，上着呼吸機，上着ECMO。那麼看現在，我們作爲一個臨牀醫生的角度，現在的奧密克戎和那會兒我們的流感比，它導致肺炎或者甚至說重症或者危重症的比例比流感還低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
